EAN 2023 | MRI data from N-MOmentum: impact of inebilizumab on subclinical spinal lesions in NMOSD

Bruce Cree, MD, PhD, MAS, from the University of California, San Francisco, CA, discusses a new analysis of MRI data from the N-MOmentum clinical trial (NCT02200770) of inebilizumab treatment for neuromyelitis optica spectrum disorder (NMOSD). The pivotal Phase III trial used MRI to help confirm the occurrence NMO attacks, correlating MRI data with clinical information. In this analysis, researchers noted a reduction in the formation of subclinical transverse myelitis lesions in people with NMOSD treated with inebilizumab. The analysis also showed an association between these subclinical spinal cord lesions and likelihood of future attacks. Overall, these findings offer new insights into the significance of subclinical MRI findings on the spinal cord as a potential signal of future attacks. Recorded at the 9th Congress of the European Academy of Neurology (EAN) 2023 held in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.